A new design of the continual reassessment method
From MaRDI portal
Publication:5082671
DOI10.1080/03610918.2019.1592191zbMath1497.62291OpenAlexW2934973407MaRDI QIDQ5082671
Po Yang, Xikui Wang, Weijia Zhang
Publication date: 21 June 2022
Published in: Communications in Statistics - Simulation and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610918.2019.1592191
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Related Items (1)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Adaptive clinical trial designs for phase I cancer studies
- Cumulative cohort design for dose-finding
- Group up-and-down designs for dose-finding
- Design and Analysis of Phase I Clinical Trials
- Consistency of continual reassessment method under model misspecification
- Miscellanea. A stopping rule for the continual reassessment method
- Continual Reassessment Method: A Likelihood Approach
- A Random Walk Rule for Phase I Clinical Trials
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- Simple benchmark for complex dose finding studies
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Continual reassessment designs with early termination
This page was built for publication: A new design of the continual reassessment method
